FOR IMMEDIATE RELEASE
Leading Global Clinical Research Organization Leverages Medidata’s ASPire to Win™
Program to Increase Clinical Trial Efficiencies
NEW YORK, NY – April 3, 2006 – Medidata Solutions, a global provider of electronic clinical data capture, management and reporting solutions, today announced it has entered into a strategic relationship with Kendle (Nasdaq: KNDL), a leading global fullservice clinical research organization (CRO). Through Medidata’s ASPire to Win Program, Kendle will use Medidata Rave to enhance its electronic data capture (EDC) management and analysis functions for Phase II–IV clinical studies.
Kendle selected Medidata Rave based on its advanced global capabilities and widespread user appeal. Rave will enable Kendle to offer its biopharmaceutical customers an EDC solution that will increase site adoption by providing remote access to data and reports in real-time and offering the ability to clean and lock data more rapidly. In addition, Rave’s unique local language and translation features will support Kendle’s focus on continued growth and expansion in Latin America, Central and Eastern Europe, Asia/Pacific and Africa.
Medidata’s ASPire to Win Program is a non-exclusive application service provider (ASP) partnership and business model, enabling Kendle to become Medidata Ravetrained and certified. This will allow Kendle to offer the Rave platform in-house, draw on Medidata’s expertise, and ultimately expedite the delivery of clinical trial data for the company’s customers.
“Our strategic relationship with Medidata will provide a stable, robust, intuitive and flexible architecture to help maximize product life cycles,” said Gregg Dearhammer, vice president, biometrics, Kendle. “Medidata’s proven track record and our shared customer base will ensure a smooth transition to the Rave solution.”
“Kendle is a natural partner for us as both companies continue to expand international reach and drive clinical trial efficiencies,” said Tarek Sherif, CEO of Medidata Solutions. “We are excited for Kendle to become an ASPire to Win partner, and look forward to enhancing the company’s skills and capabilities to cost-effectively implement advanced clinical trial technology.”
Kendle has begun customer implementation primarily across Phase II–IV clinical studies and expects implementation of Rave to be completed in May.
About Kendle
Kendle International Inc. (Nasdaq: KNDL) is among the world’s leading global clinical research organizations. The company delivers innovative and robust clinical development solutions—from first-in-human studies through market launch and surveillance—to help the world’s biopharmaceutical companies maximize product life cycles and grow market share. With the expertise of its nearly 2,000 associates worldwide, Kendle has conducted clinical trials or provided regulatory, pharmacovigilance and validation services in 70 countries. Kendle was the 10th best-performing stock on the Nasdaq for 2005. Additional information and investor kits are available upon request from Kendle, 1200 Carew Tower, 441 Vine Street, Cincinnati, OH 45202, or from our corporate Web site at www.kendle.com.
About Medidata Solutions Worldwide
Medidata Solutions helps the world’s leading pharmaceutical, biotechnology and medical device companies realize the maximum potential value from their clinical research investments. Working with companies large and small, Medidata Solutions helps accelerate the process of bringing life-enhancing treatments to market—on five continents and in more than 70 countries. Innovative process design, technology and services can streamline clinical trials by providing early visibility to clinical data for faster decision-making, optimized resources and lower execution risk. Medidata Solutions’ broad client base and deep clinical experience provide value for the world’s leading pharmaceutical, biotechnology and medical device companies, expertise in more than 20 therapeutic areas, projects in Phase I, II, III, IV, registries and surveillance, and studies with thousands of investigators and tens-of-thousands of subjects. To learn more about Medidata Solutions, please visit www.mdsol.com.
Contact:
Susan Lombardo
Lois Paul & Partners
781.782.5767
Susan_Lombardo@lpp.com